Dashboard
Manage Tickers

NVRONEVRO CORP

NYSE nevro.com


$ 11.28 $ 0.14 (1.26 %)    

Friday, 03-May-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 11.29
$ 11.70
$ 0.00 x 0
$ 0.00 x 0
$ 11.14 - $ 11.70
$ 10.27 - $ 28.89
373,702
na
406.23M
$ 1.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-23-2024 12-31-2023 10-K
2 11-01-2023 09-30-2023 10-Q
3 08-01-2023 06-30-2023 10-Q
4 04-26-2023 03-31-2023 10-Q
5 02-21-2023 12-31-2022 10-K
6 11-02-2022 09-30-2022 10-Q
7 08-03-2022 06-30-2022 10-Q
8 05-04-2022 03-31-2022 10-Q
9 02-23-2022 12-31-2021 10-K
10 11-08-2021 09-30-2021 10-Q
11 08-04-2021 06-30-2021 10-Q
12 05-05-2021 03-31-2021 10-Q
13 02-24-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-05-2020 06-30-2020 10-Q
16 05-05-2020 03-31-2020 10-Q
17 02-25-2020 12-31-2019 10-K
18 11-06-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 02-21-2019 12-31-2018 10-K
22 11-05-2018 09-30-2018 10-Q
23 08-02-2018 06-30-2018 10-Q
24 05-07-2018 03-31-2018 10-Q
25 02-22-2018 12-31-2017 10-K
26 11-06-2017 09-30-2017 10-Q
27 08-07-2017 06-30-2017 10-Q
28 05-08-2017 03-31-2017 10-Q
29 02-23-2017 12-31-2016 10-K
30 11-07-2016 09-30-2016 10-Q
31 08-08-2016 06-30-2016 10-Q
32 05-09-2016 03-31-2016 10-Q
33 02-29-2016 12-31-2015 10-K
34 11-09-2015 09-30-2015 10-Q
35 08-06-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 03-18-2015 12-31-2014 10-K
38 12-02-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

rbc-capital-maintains-sector-perform-on-nevro-lowers-price-target-to-16
RBC Capital Maintains Sector Perform on Ne...
04/15/2024 18:21:39

RBC Capital analyst Shagun Singh maintains Nevro (NYSE:NVRO) with a Sector Perform and lowers the price target from $18 to $16.

mizuho-maintains-neutral-on-nevro-lowers-price-target-to-16
Mizuho Maintains Neutral on Nevro, Lowers ...
04/11/2024 11:38:47

Mizuho analyst Anthony Petrone maintains Nevro (NYSE:NVRO) with a Neutral and lowers the price target from $20 to $16.

wells-fargo-maintains-equal-weight-on-nevro-lowers-price-target-to-14
Wells Fargo Maintains Equal-Weight on Nevr...
04/08/2024 12:37:12

Wells Fargo analyst Larry Biegelsen maintains Nevro (NYSE:NVRO) with a Equal-Weight and lowers the price target from $17 to ...

where-nevro-stands-with-analysts
Where Nevro Stands With Analysts
04/03/2024 17:01:14

citigroup-maintains-neutral-on-nevro-lowers-price-target-to-16
Citigroup Maintains Neutral on Nevro, Lowe...
04/03/2024 15:56:58

Citigroup analyst Joanne Wuensch maintains Nevro (NYSE:NVRO) with a Neutral and lowers the price target from $18 to $16.

nevro-receives-fda-510k-clearance-to-use-si-fixation-system-without-need-to-include-lateral-screw
Nevro Receives FDA 510(k) Clearance To Use...
02/28/2024 21:54:13

Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint FusionREDWOOD CITY, Calif., Feb. 2...

analyst-scoreboard-4-ratings-for-nevro
Analyst Scoreboard: 4 Ratings For Nevro
02/22/2024 14:00:47

nevro-expects-worldwide-revenue-of-435m-445m-for-full-year-2024-est-44454m-97m-99m-for-q1-est-9872m
Nevro Expects Worldwide Revenue Of $435M-$...
02/21/2024 22:15:38

nevro-enters-cooperation-agreement-with-engaged-capital-appoints-kirt-p-karros-to-board
Nevro Enters Cooperation Agreement With En...
02/21/2024 21:58:29

nevro-q4-2023-gaap-eps-025-beats-049-estimate-sales-11618m-beat-11248m-estimate
Nevro Q4 2023 GAAP EPS $(0.25) Beats $(0.4...
02/21/2024 21:30:55

Nevro (NYSE:NVRO) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.49) by 48.98 ...

nevro-q4-earnings-insights
Nevro: Q4 Earnings Insights
02/21/2024 21:30:13

earnings-scheduled-for-february-21-2024
Earnings Scheduled For February 21, 2024
02/21/2024 10:09:04

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on...

nevro-announces-coverage-update-from-carelon-healthcare-for-the-treatment-of-painful-diabetic-neuropathy
Nevro Announces Coverage Update From Carel...
01/18/2024 21:19:22

Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...

nevro-to-highlight-25-scientific-abstracts-at-2024-north-american-neuromodulation-society-annual-meeting
Nevro To Highlight 25 Scientific Abstracts...
01/17/2024 21:20:34

Presentations review clinical results of 10 kHz Therapy™ for the treatment of chronic backand leg pain, non-surgical back pain ...

what-analysts-are-saying-about-nevro-stock
What Analysts Are Saying About Nevro Stock
01/12/2024 12:00:20

rbc-capital-downgrades-nevro-to-sector-perform-lowers-price-target-to-20
RBC Capital Downgrades Nevro to Sector Per...
01/12/2024 11:13:30

RBC Capital analyst Shagun Singh downgrades Nevro (NYSE:NVRO) from Outperform to Sector Perform and lowers the price target ...

nevro-announces-restructuring-including-laying-off-63-employees-by-end-of-q1-2024
Nevro Announces Restructuring, Including L...
01/09/2024 13:41:37

The layoffs affect employees in corporate, sales and marketing, and operations positions but are largely focused on internally ...

nevro-sees-prelim-fy23-revenue-425m-vs-41833m-est
Nevro Sees Prelim. FY23 Revenue $425M Vs $...
01/09/2024 13:40:03

nevro-sees-prelim-q4-revenue-116m-vs-10926m-est
Nevro Sees Prelim. Q4 Revenue $116M Vs $10...
01/09/2024 13:39:24

nevro-filed-prospectus-for-offering-of-up-to-25m-shares-of-common-stock-offered-by-selling-securityholde
Nevro Filed Prospectus For Offering Of Up ...
12/29/2023 11:05:14

-S-3

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION